POONGJEON PHARMACY CO., LTD.
KKRX:2980602,200.00
KRW
0.00
(0.00%)
ISIN
KR7298060005
Return %
Stock
S&P 500
1Y
-59.07
14.20
3Y
-80.44
81.12
5Y
-97.12
68.34
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Yoo-Jung Kim
- Full Time Employees
- 25
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Inchon South Korea
- IPO Date
- Jun 17, 2020
- Website
- scmlifescience.com
- Similar Companies
- Business
- POONGJEON PHARMACY CO., LTD., formerly known as SCM Lifescience Co., Ltd., is a South Korea-based healthcare company engaged in pharmaceutical wholesale distribution, stem cell therapeutics research and development, and cosmeceutical manufacturing. The company operates through three primary business divisions: Pharmaceutical Wholesale and Distribution, Biopharmaceuticals and Stem Cell Therapeutics, and Derma Cosmetics. Its core product and service offerings comprise the wholesale distribution of prescription pharmaceuticals, over-the-counter medicines, and medical supplies to university hospitals, general medical centers, and healthcare institutions across South Korea; the clinical development of allogeneic bone marrow-derived mesenchymal stem cell (MSC) therapeutics utilizing a proprietary Subfractionation Culturing Method for immunological and inflammatory indications, including candidate SCM-AGH for moderate-to-severe atopic dermatitis and acute pancreatitis, and candidate SCM-CGH for chronic graft-versus-host disease; and the manufacturing and commercialization of anti-aging skincare, hair loss prevention, and scalp-care cosmetics formulated with stem cell conditioned media under the proprietary brand name iroro, including the iroro Dearscalp and iroro Nuwon product lines. Founded in July 2014 and headquartered in Incheon, South Korea, the company maintains research partnerships with academic institutions, including Inha University and Inha University Hospital, to advance high-purity stem cell separation technologies. In recent major corporate developments, the company executed a strategic absorption and merger of its 100%-owned pharmaceutical wholesale subsidiary Poongjeon Pharmacy to secure immediate commercial revenue streams and strengthen cash flow stability, followed by an official corporate name change from SCM Lifescience Co., Ltd. to POONGJEON PHARMACY CO., LTD. in March 2026. Concurrently, the company implemented strategic adjustments to its clinical pipeline prioritization, undertook paid-in capital increases to bolster its balance sheet and regulatory listing compliance on the KOSDAQ market, and restructured executive leadership under Chief Executive Officer Kim Yu-jeong to drive its integrated pharmaceutical distribution and biotechnology business model.